var data={"title":"Peramivir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Peramivir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/400470?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">see &quot;Peramivir: Drug information&quot;</a> and <a href=\"topic.htm?path=peramivir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Peramivir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50907064\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=13045\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=13045\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26819872\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rapivab</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49909724\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Rapivab</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600881\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Neuraminidase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444121\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Influenza, treatment:</b> Very limited data available. <b>Note:</b> During the 2009 influenza season, peramivir was given as part of an Emergency Use Authorization in the US for patients with pandemic A (H1N1) 2009 virus (FDA 2009). Subsequently, the drug has been studied but is not approved for use in hospitalized patients and/or patients with complicated influenza (de Jong 2014; Sugaya 2012). Full-term neonate: IV: 6 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Dosage must be adjusted in patients with a CrCl &lt;50 mL/minute. <b>Note:</b> Dosage adjustments based on Schwartz formula (FDA 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 31 to 49 mL/minute/1.73 m<sup>2</sup>: 1.5 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 30 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup> (<b>not</b> on intermittent hemodialysis [HD] or continuous renal replacement therapy [CRRT]): 1 mg/kg/dose on day 1, followed by 0.15 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup> (<b>on</b> intermittent HD): 1 mg/kg/dose on day 1, followed by 1 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600889\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">see &quot;Peramivir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza (acute, uncomplicated), treatment:</b> <b>Note: </b>Administer within 2 days of onset of symptoms of influenza.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years: IV: 12 mg/kg as a single dose; maximum dose: 600 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: 600 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza (hospitalized, high risk, and/or epidemic), treatment: </b>Limited data available; optimal dosing not established. <b>Note:</b> During the 2009 influenza season, peramivir was given as part of an Emergency Use Authorization in the US for patients with pandemic A (H1N1) 2009 virus (FDA 2009). Subsequently, the drug has been studied but is not approved for use in hospitalized patients and/or patients with complicated influenza (de Jong 2014; Sugaya 2012). Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">29 to 30 days of life: 6 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014); others have used 10 mg/kg/dose once daily (Komeda 2014; Sugaya 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">31 to 90 days of life: 8 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014); others have used 10 mg/kg/dose once daily (Komeda 2014; Sugaya 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">91 to 180 days of life: 10 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014; Komeda 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">181 days of life through 5 years: 12 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014); others have used 10 mg/kg/dose once daily (Komeda 2014; Sugaya 2012); maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 to 17 years: 10 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata, 2014; Komeda 2014); maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;18 years: 600 mg once daily for 5 to 10 days (Hata 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza (acute, uncomplicated):</b> IV: 600 mg as a single dose; initiate within 2 days of onset of symptoms of influenza</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Influenza (hospitalized, high-risk):</b> IV: 600 mg once daily for up to 5 to 10 days (de Jong 2014; Ison 2014; Kohno 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated influenza: </i>Children &ge;2 years and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 49 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;2 years: 4 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: 200 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;2 years: 2 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: 100 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring hemodialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;2 years: 2 mg/kg as a single dose, administered after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: 100 mg as a single dose; administered after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hospitalized (high-risk and/or epidemic) patients with influenza:</i> Limited data available: Dosing adjustment based on recommendations from H1N1 epidemic 2009 to 2010 (FDA 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &lt;18 years: <b>Note:</b> Dosage adjustment based on renal function estimated using the Schwartz equation.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 31 to 49 mL/minute/1.73 m<sup>2</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">29 to 30 days of life: 1.5 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">31 to 90 days of life: 2 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">91 to 180 days of life: 2.5 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">181 days of life through 5 years: 3 mg/kg/dose once daily for 5 to 10 days; maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">6 to 17 years: 2.5 mg/kg/dose once daily for 5 to 10 days; maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 30 mL/minute/1.73 m<sup>2</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">29 to 30 days of life: 1 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">31 to 90 days of life: 1.3 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">91 to 180 days of life: 1.6 mg/kg/dose once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">181 days of life through 5 years: 1.9 mg/kg/dose once daily for 5 to 10 days; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">6 to 17 years: 1.6 mg/kg/dose once daily for 5 to 10 days; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup> (<b>not</b> on intermittent hemodialysis [HD] or continuous renal replacement therapy [CRRT]):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">29 to 30 days of life: 1 mg/kg/dose on day 1, followed by 0.15 mg/kg/dose once daily for a total of 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">31 to 90 days of life: 1.3 mg/kg/dose on day 1, followed by 0.2 mg/kg/dose once daily for a total of 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">91 to 180 days of life: 1.6 mg/kg/dose on day 1, followed by 0.25 mg/kg/dose once daily for a total of 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">181 days of life through 5 years: 1.9 mg/kg/dose on day 1 (maximum dose day 1: 100 mg/dose), followed by 0.3 mg/kg/dose once daily for a total of 5 to 10 days; maximum dose: 15 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">6 to 17 years: 1.6 mg/kg/dose on day 1 (maximum dose day 1: 100 mg/dose), followed by 0.25 mg/kg/dose once daily for a total of 5 to 10 days; maximum dose: 15 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup> (<b>on</b> intermittent HD):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">29 to 30 days of life: 1 mg/kg/dose on day 1, followed by 1 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">31 to 90 days of life: 1.3 mg/kg/dose on day 1, followed by 1.3 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">91 to 180 days of life: 1.6 mg/kg/dose on day 1, followed by 1.6 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">181 days of life through 5 years: 1.9 mg/kg/dose on day 1, followed by 1.9 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b>; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">6 to 17 years: 1.6 mg/kg/dose on day 1, followed by 1.6 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b>; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CRRT: Limited data exist. Estimate total clearance by calculating CRRT clearance (CL<sub>CRRT</sub>) depending on CRRT modality used (eg, CVVHD, Slow continuous ultrafiltration [SCUF]), plus any residual renal function, and adjust dosage according to CrCl recommendation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years: <b>Note:</b> Dosage adjustment based on renal function estimated using the Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;50 mL/minute: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 31 to 49 mL/minute: 150 mg once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 30 mL/minute: 100 mg once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute (not on renal replacement therapy): 100 mg on day 1, followed by 15 mg once daily for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis (HD): 100 mg on day 1, followed by 100 mg given 2 hours after each HD session on dialysis days only</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated influenza: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 49 mL/minute: 200 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute: 100 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring intermittent hemodialysis (IHD): 100 mg as a single dose, administered after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>\n        <i>Hospitalized (high-risk) patients with influenza (FDA 2009):</i></i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: 600 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 31 to 49 mL/minute: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 30 mL/minute: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute (not on renal replacement therapy): 100 mg once daily on day 1, then 15 mg once daily beginning on day 2</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring IHD: 100 mg on day 1, then 100 mg given 2 hours after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Pharmacokinetic data indicate that peramivir is efficiently cleared by CRRT due to high sieving coefficient and low protein binding (Bazan 2010; Bentley 2014; Scheetz 2011). One suggested method for determining the dose of peramivir while on CRRT, assuming a sieving coefficient of 100% and negligible protein binding, is to estimate the patient's total clearance based on the following equation and refer to the above renal dosage adjustments for dose selection (FDA 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Total clearance</b> = Residual renal function (mL/minute) + CRRT clearance (CL<sub>CRRT</sub>) (mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CL<sub>CRRT</sub> can be determined as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CVVH/Continuous arteriovenous hemofiltration (CAVH)/Slow continuous ultrafiltration (SCUF): Use ultrafiltration rate (mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CAVHD/CVVHD: Use dialysate flow rate (mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Continuous arteriovenous hemodialysis (CAVHDF)/CVVHDF: Use total of ultrafiltration rate and dialysate flow rate (mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, not significantly metabolized hepatically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524105\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rapivab: 200 mg/20 mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26819871\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600890\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: For IV use only, do not administer intramuscularly. Administer diluted dose intravenously over 15 to 30 minutes; in some pediatric studies, infusion times up to 60 minutes has been used (Komeda 2014; Sugaya 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26726839\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials in original carton at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). After dilution, administer immediately or store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 24 hours. Discard unused diluted solution after 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9601645\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute, uncomplicated influenza in patients who have been symptomatic &le;2 days (FDA approved in ages &ge;2 years and adults). <b>Note:</b> Efficacy has not been established for patients with serious influenza requiring hospitalization; efficacy is based on clinical trials in which influenza A was the predominant virus; a limited number of subjects with influenza B have been studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27106545\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine: Increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, diarrhea, vomiting (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Proteinuria (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic and oncologic: Neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal behavior, anaphylactoid reaction, anaphylaxis, delirium, erythema multiforme, exfoliative dermatitis, hallucination, skin rash, Stevens-Johnson syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523426\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Serious hypersensitivity or anaphylaxis to peramivir or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523946\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic reactions: Rare serious skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome) have been reported. If skin reactions are suspected or occur, discontinue infusion immediately and institute appropriate supportive treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Serious hypersensitivity reactions (eg, anaphylaxis) have been reported. Discontinue infusion immediately and institute appropriate supportive treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuropsychiatric events: Rare occurrences of neuropsychiatric events (including abnormal behavior, delirium, and hallucinations), including fatalities have been reported, primarily among pediatric patients. Onset is often abrupt and subsequent resolution is rapid. These events may occur in patients with encephalitis, encephalopathy, or in uncomplicated influenza. Closely monitor for signs of abnormal behavior.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Elimination is primarily renal; dosage adjustment is required in patients with CrCl &lt;50 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Emergence of resistance substitutions or other factors (eg, viral virulence) could decrease drug effectiveness. Consider available information on influenza drug susceptibility patterns/treatment effects when using; efficacy in patients with serious influenza requiring hospitalization has not been established. Has not been shown to prevent secondary serious bacterial infections occurring during influenza course; if bacterial infections occur, treat with antibiotics as appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26726826\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric trials, most frequently reported adverse effects included diarrhea and abnormal behavior (Komeda 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26736612\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9613155\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13045&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26726821\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Information related to the use of peramivir in pregnancy is limited (Hernandez 2011; Sorbello 2012). Based on information from one case, the pharmacokinetics of peramivir may be changed with pregnancy (Clay 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother (CDC 62[07], 2013). Neuraminidase inhibitors are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks postpartum (CDC 60[1], 2011; CDC March 13, 2014; CDC January 2015). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600891\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (prior to initiation and during therapy); development of diarrhea; signs or symptoms of unusual behavior (including attempts at self-injury, confusion, and/or delirium), rash after administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523513\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Peramivir, a cyclopentane analogue, selectively inhibits the influenza virus neuraminidase enzyme, preventing the release of viral particles from infected cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26726876\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 12.56 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not significantly metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Low (investigational agent) (Hata 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~90% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26844478\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rapivab Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $380.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26999114\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Peramiflu (KR);</li>\n      <li>Rapiacta (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25345428\"></a>Bentley ML, Hollistera AS, Hansenb AC, Smith JA, Cain JS. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. <i>Int J Clin Pharmacol Ther</i>. 2014;52(12):1105-11. doi: 10.5414/CP202161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/25345428/pubmed\" target=\"_blank\" id=\"25345428\">25345428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bazan JA, Bauer KA, Hollister AS, et al. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy. <i>Pharmacotherapy.</i> 2010;30(10):1016-1020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/20874039/pubmed\" target=\"_blank\" id=\"20874039\">20874039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR</i>. 2011; 60(1):1-28.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC health update regarding treatment of patients with influenza with antiviral medications. January 9, 2015. Available at <a href=\"http://emergency.cdc.gov/han/han00375.asp%20\" target=\"_blank\">http://emergency.cdc.gov/han/han00375.asp </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. March 13, 2014. Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clay PG, Adiga RB, Taylor TA, Alsup R, Gerk PM, McRae M. Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza. <i>Obstet Gynecol</i>. 2011118(2 Pt 2):463-467.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/21768855 /pubmed\" target=\"_blank\" id=\"21768855 \">21768855 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25115871\"></a>de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. <i>Clin Infect Dis</i>. 2014;59(12):e172-e185. doi: 10.1093/cid/ciu632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/25115871/pubmed\" target=\"_blank\" id=\"25115871\">25115871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). Peramivir emergency use authorization, fact sheet for health care providers. November 19, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hata A, Akashi-Ueda R, Takamatsu K, Matsumura T. Safety and efficacy of peramivir for influenza treatment. <i>Drug Des Devel Ther</i>. 2014;8:2017-2038<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/25368514 /pubmed\" target=\"_blank\" id=\"25368514 \">25368514 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. <i>Clin Infect Dis</i>. 2011;52(6):695-706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/21367722 /pubmed\" target=\"_blank\" id=\"21367722 \">21367722 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23985625\"></a>Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. <i>Antivir Ther</i>. 2014;19(4):349-361. doi: 10.3851/IMP2680.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/23985625/pubmed\" target=\"_blank\" id=\"23985625\">23985625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21464252\"></a>Kohno S, Kida H, Mizuguchi M, et al; S-021812 Clinical Study Group. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. <i>Antimicrob Agents Chemother</i>. 2011;55(6):2803-2812. doi: 10.1128/AAC.01718-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/21464252/pubmed\" target=\"_blank\" id=\"21464252\">21464252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): a pediatric drug use investigation. J<i> Infect Chemother</i>. November 26, 2014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/25523716 /pubmed\" target=\"_blank\" id=\"25523716 \">25523716 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Jamieson DJ, Rasmussen SA, et al, &quot;2009 Pandemic Influenza A (H1N1) Virus Infection in Postpartum Women in California,&quot; <i>Am J Obstet Gynecol</i>, 2011, 204(2):144.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/21074132/pubmed\" target=\"_blank\" id=\"21074132\">21074132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Yang S, Samuel MC, Uyeki TM, Schechter R. Neuraminidase inhibitors for critically ill children with influenza. <i>Pediatrics</i>. 2013;132(6):e1539-1545.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/24276847 /pubmed\" target=\"_blank\" id=\"24276847 \">24276847 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. <i>PLoS One</i>. 2012;7(6):e40261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/22768265 /pubmed\" target=\"_blank\" id=\"22768265 \">22768265 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Randolph AG, Vaughn F, Sullivan R, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. <i>Pediatrics</i>. 2011;128(6):e1450-1458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/22065262 /pubmed\" target=\"_blank\" id=\"22065262 \">22065262 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapivab (peramivir) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22116989\"></a>Scheetz MH, Griffith MM, Ghossein C, Hollister AS, Ison MG. Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. <i>Ann Pharmacother</i>. 2011;45(12):e64. doi: 10.1345/aph.1Q437.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/22116989/pubmed\" target=\"_blank\" id=\"22116989\">22116989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. <i>Clin Infect Dis</i>. 2012;55(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/22491501 /pubmed\" target=\"_blank\" id=\"22491501 \">22491501 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. <i>Antimicrob Agents Chemother</i>. 2012;56(1):369-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/peramivir-pediatric-drug-information/abstract-text/22024821/pubmed\" target=\"_blank\" id=\"22024821\">22024821</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13045 Version 51.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50907064\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26819872\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49909724\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F9600881\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444121\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F9600889\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9524105\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F26819871\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9600890\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F26726839\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9601645\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27106545\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9523426\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9523946\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26726826\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F26736612\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9613155\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26726821\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9600891\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9523513\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F26726876\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26844478\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26999114\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13045|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">Peramivir: Drug information</a></li><li><a href=\"topic.htm?path=peramivir-patient-drug-information\" class=\"drug drug_patient\">Peramivir: Patient drug information</a></li></ul></div></div>","javascript":null}